SG11201805150QA - Variant antibodies for site-specific conjugation - Google Patents

Variant antibodies for site-specific conjugation

Info

Publication number
SG11201805150QA
SG11201805150QA SG11201805150QA SG11201805150QA SG11201805150QA SG 11201805150Q A SG11201805150Q A SG 11201805150QA SG 11201805150Q A SG11201805150Q A SG 11201805150QA SG 11201805150Q A SG11201805150Q A SG 11201805150QA SG 11201805150Q A SG11201805150Q A SG 11201805150QA
Authority
SG
Singapore
Prior art keywords
bristol
rule
international
myers squibb
road
Prior art date
Application number
SG11201805150QA
Inventor
Paul O Sheppard
Henrik Andersen
Xiang Shao
Chetana Rao-Naik
Arvind Rajpal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201805150QA publication Critical patent/SG11201805150QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011101110111110101011111111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... .....!;,,, 29 June 2017(29.06.2017) WIPO I PCT WO 2017/112624 Al (51) International Patent Classification: DO, C07K 16/00 (2006.01) A61K 47/68 (2017.01) HN, KP, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2016/067663 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, 20 December 2016 (20.12.2016) TH, ZA, ZM, ZW. RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, 62/270,245 21 December 2015 (21.12.2015) US TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY DK, [US/US]; Route 206 and Province Line Road, Princeton, LV, New Jersey 08543 (US). SM, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: SHEPPARD, Paul 0.; 13532 278th Drive NE, GW, KM, ML, MR, NE, SN, TD, TG). Granite Falls, Washington 98252 (US). ANDERSEN, Declarations under Rule 4.17: Henrik c/o Bristol-Myers Squibb Company, 38 Jackson as to applicant's entitlement to apply for and be granted a — Road, Devens, Massachusetts 01434 (US). SHAO, Xiang; patent (Rule 4.17(H)) c/o Bristol-Myers Squibb Company, 700 Bay Road, Red- wood City, California 94063 (US). RAO-NAIK, Chetana; — as to the applicant's entitlement to claim the priority of the c/o Bristol-Myers Squibb Company, 700 Bay Road, Red- earlier application (Rule 4.17(iii)) wood City, California 94063 (US). RAJPAL, Arvind; c/o of inventorship (Rule 4.17(iv)) Bristol-Myers Squibb Company, 700 Bay Road, Redwood = City, California 94063 (US). Published: Agents: CHAO, Yuan et al.; Bristol-Myers Squibb Com- — with (74) international search report (Art. 21(3)) = pany, Route 206 and Province Line Road, Princeton, New — before the expiration of the time limit for amending the Jersey 08543 (US). claims and to be republished in the event of receipt of Designated States (unless otherwise indicated, for every amendments (Rule 48.2(h)) = (81) kind of national protection available): AE, AG, AL, AM, — with AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, sequence listing part of description (Rule 5.2(a)) — = BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, = = = = = = Il 7r N N Il Il IN Il 0 \" (54) Title: VARIANT ANTIBODIES FOR SITE-SPECIFIC CONJUGATION (:) ,.. (57) : Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.
SG11201805150QA 2015-12-21 2016-12-20 Variant antibodies for site-specific conjugation SG11201805150QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270245P 2015-12-21 2015-12-21
PCT/US2016/067663 WO2017112624A1 (en) 2015-12-21 2016-12-20 Variant antibodies for site-specific conjugation

Publications (1)

Publication Number Publication Date
SG11201805150QA true SG11201805150QA (en) 2018-07-30

Family

ID=57944491

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805150QA SG11201805150QA (en) 2015-12-21 2016-12-20 Variant antibodies for site-specific conjugation

Country Status (13)

Country Link
US (1) US20180362619A1 (en)
EP (1) EP3394096A1 (en)
JP (1) JP2019505575A (en)
KR (1) KR20180089433A (en)
CN (1) CN108431034A (en)
AU (1) AU2016377371A1 (en)
BR (1) BR112018012524A2 (en)
CA (1) CA3008678A1 (en)
EA (1) EA201891482A1 (en)
IL (1) IL260049A (en)
MX (1) MX2018007479A (en)
SG (1) SG11201805150QA (en)
WO (1) WO2017112624A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200040819A (en) 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 Anti-CTLA-4 probody treatment for targeting antibodies
CA3076867A1 (en) 2017-10-03 2019-04-11 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
JP4118462B2 (en) 1999-07-19 2008-07-16 株式会社リコー Portable electronic devices
KR100942863B1 (en) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 Human ctla-4 antibodies and their uses
KR100668538B1 (en) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Human Monoclonal Antibodies against CD30
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004110498A2 (en) 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
WO2005010048A2 (en) 2003-07-22 2005-02-03 Schering Aktiengesellschaft Rg1 antibodies and uses thereof
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CN102838675B (en) 2003-12-10 2014-07-30 梅达雷克斯有限责任公司 Ip-10 antibodies and their uses
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
CN101124249B (en) 2005-02-18 2011-06-29 米德列斯公司 Human monoclonal antibodies to prostate specific membrane antigen(PSMA)
KR101291640B1 (en) 2005-02-18 2013-08-05 메다렉스, 엘.엘.시. Monoclonal antibodies against prostate specific membrane antigen(psma) lacking in fucosyl residues
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
PL1957539T3 (en) 2005-12-08 2013-08-30 Squibb & Sons Llc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
CA2638902C (en) 2005-12-08 2014-09-23 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
PE20080316A1 (en) 2006-05-25 2008-04-10 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE COMPOUNDS
PE20080102A1 (en) 2006-05-25 2008-02-11 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
EP2035554B1 (en) 2006-06-29 2013-04-24 The Board of Trustees of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
CN101528914B (en) 2006-09-08 2014-12-03 Ambrx公司 Site specific incorporation of non-natural amino acids by vertebrate cells
SI2066351T1 (en) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Human antibodies that bind cxcr4 and uses thereof
KR20150067395A (en) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. Human antibodies that bind cd22 and uses thereof
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
UY30776A1 (en) 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
SI2178921T1 (en) 2007-07-17 2016-05-31 E.R. Squibb & Sons, L.L.C. Monoclonal antibodies against glypican-3
EP2195017B1 (en) 2007-10-01 2014-10-22 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
CN103068405A (en) 2010-04-15 2013-04-24 西雅图基因公司 Targeted pyrrolobenzodiazapine conjugates
CN102971329B (en) 2010-04-15 2016-06-29 麦迪穆有限责任公司 Pyrrolobenzodiazepines for treating proliferative disease is tall and erect
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
JP6099336B2 (en) 2011-09-14 2017-03-22 株式会社半導体エネルギー研究所 Light emitting device
AU2012311505B2 (en) 2011-09-20 2016-09-29 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
EP2863955B1 (en) * 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
AU2014214751B2 (en) 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
LT2956173T (en) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
EA201690388A1 (en) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити NEW DERIVATIVES OF UNCIALAMICINE, METHODS OF THEIR SYNTHESIS AND THEIR APPLICATION AS ANTI-TUMOR AGENTS
BR112016020065A2 (en) 2014-03-12 2018-02-20 Novartis Ag specific sites to modify antibodies to make immunoconjugates
RU2711485C2 (en) 2014-04-11 2020-01-17 МЕДИММЬЮН, ЭлЭлСи Conjugated compounds containing cysteine-constructed antibodies
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
US20170304460A1 (en) 2014-10-01 2017-10-26 Medimmune, Llc Method of conjugating a polypeptide

Also Published As

Publication number Publication date
AU2016377371A1 (en) 2018-08-09
EA201891482A1 (en) 2018-12-28
JP2019505575A (en) 2019-02-28
US20180362619A1 (en) 2018-12-20
CN108431034A (en) 2018-08-21
EP3394096A1 (en) 2018-10-31
KR20180089433A (en) 2018-08-08
WO2017112624A1 (en) 2017-06-29
BR112018012524A2 (en) 2018-12-11
CA3008678A1 (en) 2017-06-29
MX2018007479A (en) 2018-08-01
IL260049A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
SG11201902857SA (en) Activatable anti-ctla-4 antibodies and uses thereof
SG11201408261UA (en) Syringe
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201803906PA (en) Control of cellular redox levels
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201907209QA (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201804674UA (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201406625XA (en) Anti-fcrn antibodies
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof